CN105695400A - 一种纯化干细胞来源的心肌细胞的无血清培养基 - Google Patents
一种纯化干细胞来源的心肌细胞的无血清培养基 Download PDFInfo
- Publication number
- CN105695400A CN105695400A CN201610163672.3A CN201610163672A CN105695400A CN 105695400 A CN105695400 A CN 105695400A CN 201610163672 A CN201610163672 A CN 201610163672A CN 105695400 A CN105695400 A CN 105695400A
- Authority
- CN
- China
- Prior art keywords
- serum
- free medium
- cell
- stem cell
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 65
- 230000002107 myocardial effect Effects 0.000 title claims abstract description 35
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 19
- 239000012679 serum free medium Substances 0.000 title claims abstract description 15
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 10
- 150000001413 amino acids Chemical class 0.000 claims abstract description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 7
- 239000011573 trace mineral Substances 0.000 claims abstract description 7
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 5
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 5
- 102000004877 Insulin Human genes 0.000 claims abstract description 5
- 108090001061 Insulin Proteins 0.000 claims abstract description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 5
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 5
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940125396 insulin Drugs 0.000 claims abstract description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000008101 lactose Substances 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 5
- 235000005875 quercetin Nutrition 0.000 claims abstract description 5
- 229960001285 quercetin Drugs 0.000 claims abstract description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 3
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 3
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 3
- 239000011719 vitamin A Substances 0.000 claims abstract description 3
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 3
- 239000011718 vitamin C Substances 0.000 claims abstract description 3
- 229940045997 vitamin a Drugs 0.000 claims abstract description 3
- 239000001963 growth medium Substances 0.000 claims description 16
- 238000000746 purification Methods 0.000 claims description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 229940024606 amino acid Drugs 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 235000020776 essential amino acid Nutrition 0.000 claims description 6
- 239000003797 essential amino acid Substances 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 claims description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 229960005261 aspartic acid Drugs 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 235000004400 serine Nutrition 0.000 claims description 4
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- 229930064664 L-arginine Natural products 0.000 claims description 2
- 235000014852 L-arginine Nutrition 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052793 cadmium Inorganic materials 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- 229910052732 germanium Inorganic materials 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 235000004554 glutamine Nutrition 0.000 claims description 2
- 229960002885 histidine Drugs 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 229960004452 methionine Drugs 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 235000013930 proline Nutrition 0.000 claims description 2
- 229910052701 rubidium Inorganic materials 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 229960002898 threonine Drugs 0.000 claims description 2
- 229910052718 tin Inorganic materials 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 235000002374 tyrosine Nutrition 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 229910052726 zirconium Inorganic materials 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 7
- 241000700605 Viruses Species 0.000 abstract description 5
- 238000004113 cell culture Methods 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 239000002609 medium Substances 0.000 abstract description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 abstract 1
- 229930182816 L-glutamine Natural products 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 125000001246 bromo group Chemical group Br* 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 239000005549 deoxyribonucleoside Substances 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 5
- 239000000306 component Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000005284 basis set Methods 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 238000012832 cell culture technique Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0657—Cardiomyocytes; Heart cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/40—Nucleotides, nucleosides or bases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明属于生物技术细胞培养技术领域,具体为一种纯化干细胞来源的心肌细胞的无血清培养基。其组分包括:L-谷氨酰胺、胰岛素、维生素、基因重组人血白蛋白、氨基酸、非必需氨基酸、微量元素、乳糖、槲皮素、溴脱氧核苷、RPMI无糖培养基;其中,L-谷氨酰胺0.1-5mmol/L、胰岛素2-10mmol/L、维生素A 0-800μg/mL、维生素C(L-抗坏血酸-2-磷酸酯)100-300μg/mL、基因重组人血白蛋白0.1-2mg/mL、氨基酸0.1%-5%、非必需氨基酸1%-5%、微量元素0.1%-0.5%。该培养基可以帮助提纯混合体系的心肌细胞,其他的非心肌细胞在细胞混合物中比例逐渐降低,最后获得纯度高的心肌细胞。此培养基不含血,避免了病毒污染造成的危害。
Description
技术领域
本发明属于生物细胞培养技术领域,具体涉及一种纯化干细胞来源的心肌细胞的无血清培养基。
背景技术
细胞是生命的基本单位,犹如分子是物质的基本单位一样,细胞的功能决定了器官以及组织的功能,器官组织再构成了生命体。细胞生物学作为研究细胞的科学,研究细胞的结构,功能以及代谢、凋亡等特征和规律的一门科学。
而细胞培养技术则是在细胞生物学中最重要和最基础的技术方法手段,细胞培养是将细胞在体外环境条件下生长。细胞培养可以将细胞传代,体外培养以获得科学研究所需数量和质量的细胞,同时可以达到对细胞数量的扩增,细胞族群的筛选,细胞发育状态的变化等等目标。目前,细胞培养广泛的在生物制药、分子生物学、药物开发、医学临床上面获得应用。
在细胞培养的过程中,利用不同的培养基成分,结合特定细胞代谢特性,对特定的细胞群进行筛选,是纯化特定细胞群的方法。
心肌细胞是心脏组织的重要组成部分,数量上占心脏组织所有细胞总数的60%以上。心肌细胞的体外培养在心血管疾病研究中占据重要作用。心肌细胞可以从干细胞通过诱导分化的方式获得。干细胞是一种具有分化潜能的细胞,多种类型的干细胞均可以分化成为心肌细胞。而这些干细胞在体外特定因子诱导下变成心肌细胞和各个不同发育阶段的细胞混合物后,心肌细胞具有自发的节律性和收缩的特性。在体外分化培养过程中,很多成熟的心肌细胞的特征已经被观测到,结合现代生物技术的很多方法,如特异性抗体标记后荧光显色,电生理测试等技术手段来定性和定量的检测心肌细胞。
现有科技条件下,体外细胞培养,包括干细胞和心肌细胞的培养,大多数情况下都会用到牛血清,但是牛血清因为其成分的不确定性和外源病毒和致病因子风险,在未来细胞的临床使用中是隐患性的问题。而且牛血清产品由于不同批次以及厂家不同带来的差异太大。因此,用确定化学组分的培养基添加剂代替血清的作用,构建无血清培养基,是更优的选择方案。
发明内容
本发明的目的在于提供一种能够获得高纯度心肌细胞、且可避免病毒污染造的纯化干细胞来源的心肌细胞的无血清培养基。
本发明的培养基,可将从干细胞来源的心肌细胞从这个诱导反应获得的细胞混合物中提纯出来,让细胞种群变成单一性的心肌细胞,而去除其他未分化的细胞或者分化阶段未达到最终心肌细胞阶段的细胞,使得这个混合体系里面的心肌细胞成分中心肌细胞的比重尽量更大甚至达到纯净的心肌细胞状态。
本发明提出的纯化干细胞来源的心肌细胞的无血清培养基,其组分包括:L-谷氨酰胺、胰岛素、维生素、基因重组人血白蛋白、氨基酸、非必需氨基酸、微量元素、乳糖、槲皮素、溴脱氧核苷、RPMI无糖培养基;以RPMI无糖培养基500mL为基础,各组份的量为:
L-谷氨酰胺0.1-5mmol/L;
胰岛素2-10mmol/L;
维生素A0-800μg/mL,维生素C(L-抗坏血酸-2-磷酸酯)100-300μg/mL;
基因重组人血白蛋白0.1-2mg/mL;
氨基酸0.1%-5%;
非必需氨基酸1%-5%;
微量元素0.1%-0.5%;
乳糖的浓度为3mmol/L-5mmol/L;
槲皮素的浓度为0-10mmol/L;
溴脱氧核苷0-0.5mmol/L。
本发明中,所述的氨基酸选自L-精氨酸、L-胱氨酸、L-组氨酸、L-异亮氨酸、L-亮氨酸、L-赖氨酸、L-甲硫氨酸、L-苯丙氨酸、L-苏氨酸、L-色氨酸、L-酪氨酸、L-缬氨酸、L-丙氨酸、L-天冬氨酸、L-天冬酰胺、L-谷氨酸、甘氨酸、L-脯氨酸、L-丝氨酸中的一种或几种。
本发明中,所述的非必需氨基酸是指人体能够自身合成的氨基酸种类,选自甘氨酸、丙氨酸、脯氨酸、酪氨酸、丝氨酸、半胱氨酸、天冬酰胺、谷氨酰胺、天冬氨酸、谷氨酸中的一种或几种。
本发明中,所述的所述微量元素选自Cu、Zn、Se、Fe、Sn、Ni、Ag、Al、Cr、Ge、Zr、Rb、Co、Cd、Ba、K中的一种或几种。
本发明提出的纯化干细胞来源的心肌细胞的无血清培养基,其优点是:利用了心肌细胞和其他种类细胞可以利用不同种类的能量物质支持其生长所必须,将培养基成分敲除其他种类细胞必须的能量物质而替代用可以支撑心肌细胞生长的能量物质,这样在保证心肌细胞正常培养的情况下,也选择出了心肌细胞种群。同时配合对于干细胞有抑制作用的抑制剂,能够将目标细胞群更好的筛选出来。心肌纯化培养基中未使用牛血清,而是添加了血清的主要成分,能够减少血清带来的不确定性的影响,同时保证心肌细胞本身的活性。
此培养基不含血,为化学成分完全清楚,避免了病毒污染造成的危害。
具体实施方式
为使得本发明的操作达到预期目的,并使得优点更加明显易懂,下面结合具体实施方式对本发明作进一步详细的说明。
本发明的培养基,在干细胞诱导心肌的体系中,等待出现了成熟心肌的表征并伴有自发性搏动出现后,再由过程中预定时期内的培养基培养大约3到5天,之后换上维持心肌细胞的培养基培养培养3天。随后换上本发明中的培养基,每2-3天根据培养基消耗情况更换培养基,持续培养7-8天时间。
通过以上实施方式的描述,本领域的技术人员可以在常用的分化体系里面比较简单的实现提纯任务,并且由于培养基体系无血清参与,体系中无未知的因子参与以及无异源性的病毒污染风险,让培养后的细胞在使用上,有更好的临床使用潜力。
以上对本发明进行了详细介绍,是一种能够直接量化生产的产品,并且可以规范此类生产或者实验需求下的操作。
下表是500mLRPMI无糖培养基组配实施例:
组配1:
组配2
组配3
。
以上三组不同配方的培养基,在按照操作方法所述的培养了六天以后,经过流式细胞仪根据特异性的心肌细胞抗体TroponinT标记的细胞检测结果显示,三种培养基均提升了TroponinT表达的细胞比例。其中最后一组的表达比例最高。
Claims (4)
1.一种纯化干细胞来源的心肌细胞的无血清培养基,其特征在于,其组分为:L-谷氨酰胺、胰岛素、维生素、基因重组人血白蛋白、氨基酸、非必需氨基酸、微量元素、乳糖、槲皮素、溴脱氧核苷、RPMI无糖培养基;以RPMI无糖培养基500mL为基础,各组份的量为:
L-谷氨酰胺0.1-5mmol/L;
胰岛素2-10mmol/L;
维生素A0-800μg/mL,维生素C100-300μg/mL;
基因重组人血白蛋白0.1-2mg/mL;
氨基酸0.1%-5%;
非必需氨基酸1%-5%;
微量元素0.1%-0.5%;
乳糖的浓度为3mmol/L-5mmol/L;
槲皮素的浓度为0-10mmol/L;
溴脱氧核苷0-0.5mmol/L。
2.根据权利要求1所述的纯化干细胞来源的心肌细胞的无血清培养基,其特征在于,所述的氨基酸选自L-精氨酸、L-胱氨酸、L-组氨酸、L-异亮氨酸、L-亮氨酸、L-赖氨酸、L-甲硫氨酸、L-苯丙氨酸、L-苏氨酸、L-色氨酸、L-酪氨酸、L-缬氨酸、L-丙氨酸、L-天冬氨酸、L-天冬酰胺、L-谷氨酸、甘氨酸、L-脯氨酸、L-丝氨酸中的一种或几种。
3.根据权利要求1或2所述的纯化干细胞来源的心肌细胞的无血清培养基,其特征在于,所述的非必需氨基酸是指人体能够自身合成的氨基酸种类,选自甘氨酸、丙氨酸、脯氨酸、酪氨酸、丝氨酸、半胱氨酸、天冬酰胺、谷氨酰胺、天冬氨酸、谷氨酸中的一种或几种。
4.根据权利要求3所述的纯化干细胞来源的心肌细胞的无血清培养基,其特征在于,所述的所述微量元素选自Cu、Zn、Se、Fe、Sn、Ni、Ag、Al、Cr、Ge、Zr、Rb、Co、Cd、Ba、K中的一种或几种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610163672.3A CN105695400A (zh) | 2016-03-19 | 2016-03-19 | 一种纯化干细胞来源的心肌细胞的无血清培养基 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610163672.3A CN105695400A (zh) | 2016-03-19 | 2016-03-19 | 一种纯化干细胞来源的心肌细胞的无血清培养基 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105695400A true CN105695400A (zh) | 2016-06-22 |
Family
ID=56232392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610163672.3A Pending CN105695400A (zh) | 2016-03-19 | 2016-03-19 | 一种纯化干细胞来源的心肌细胞的无血清培养基 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105695400A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106701665A (zh) * | 2016-12-30 | 2017-05-24 | 东莞惠恩生物工程有限公司 | 人胎盘亚全能干细胞诱导分化为心肌细胞的方法及其应用 |
CN108456654A (zh) * | 2018-02-22 | 2018-08-28 | 上海产业技术研究院 | 用于促进干细胞来源心肌细胞成熟的无血清培养体系 |
CN111454886A (zh) * | 2020-05-12 | 2020-07-28 | 广东源心再生医学有限公司 | 一种增强型心肌细胞培养液及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2447191A (en) * | 2005-12-22 | 2008-09-03 | Es Cell Int Pte Ltd | Direct differentiation of cardiomyocytes from human embryonic stem cells |
WO2011160128A2 (en) * | 2010-06-18 | 2011-12-22 | Cellular Dynamics International, Inc. | Cardiomyocyte medium with dialyzed serum |
US20130029368A1 (en) * | 2011-07-29 | 2013-01-31 | Steven Kattman | Metabolic maturation in stem cell-derived tissue cells |
-
2016
- 2016-03-19 CN CN201610163672.3A patent/CN105695400A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2447191A (en) * | 2005-12-22 | 2008-09-03 | Es Cell Int Pte Ltd | Direct differentiation of cardiomyocytes from human embryonic stem cells |
WO2011160128A2 (en) * | 2010-06-18 | 2011-12-22 | Cellular Dynamics International, Inc. | Cardiomyocyte medium with dialyzed serum |
US20130029368A1 (en) * | 2011-07-29 | 2013-01-31 | Steven Kattman | Metabolic maturation in stem cell-derived tissue cells |
WO2013019661A1 (en) * | 2011-07-29 | 2013-02-07 | Cellular Dynamics International, Inc. | Metabolic maturation in stem cell-derived tissue cells |
Non-Patent Citations (3)
Title |
---|
CHUNHUI XU,ET AL: "Human Embryonic Stem Cell-Derived Cardiomyocytes Can Be Maintained in Defined Medium without Serum", 《STEM CELLS AND DEVELOPMENT》 * |
杨雷 等: "槲皮素对过氧化氢所致体外心肌细胞损伤的保护作用", 《中国临床康复》 * |
陈妍,等: "乳鼠心肌细胞的原代培养方法的改进", 《中国生物制品学杂志》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106701665A (zh) * | 2016-12-30 | 2017-05-24 | 东莞惠恩生物工程有限公司 | 人胎盘亚全能干细胞诱导分化为心肌细胞的方法及其应用 |
CN108456654A (zh) * | 2018-02-22 | 2018-08-28 | 上海产业技术研究院 | 用于促进干细胞来源心肌细胞成熟的无血清培养体系 |
CN111454886A (zh) * | 2020-05-12 | 2020-07-28 | 广东源心再生医学有限公司 | 一种增强型心肌细胞培养液及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bissell et al. | Parenchymal cells from adult rat liver in nonproliferating monolayer culture: I. Functional studies | |
CN103060264B (zh) | 一种干细胞培养基及其应用和干细胞培养方法 | |
Gatmaitan et al. | Regulation of growth and differentiation of a rat hepatoma cell line by the synergistic interactions of hormones and collagenous substrata. | |
US20090035805A1 (en) | C3A Serum-Free Clonal Cell Line and Methods of Use | |
WO2015180636A1 (zh) | 人肝细胞长期维持和增殖传代培养的专用培养基和培养方法 | |
US20200385683A1 (en) | Composition and method for culturing organoids | |
KR20060076781A (ko) | 세포 배양 배지 | |
CN109943526B (zh) | 一种促间充质干细胞增殖的无血清多肽组合物 | |
CN105695400A (zh) | 一种纯化干细胞来源的心肌细胞的无血清培养基 | |
Paul | Quiescent SV40 virus transformed 3T3 cells in culture | |
EP2265708B1 (en) | Methods for stem cell production and therapy | |
JP2021518115A (ja) | タンパク質生産の間の代謝酵素活性およびジスルフィド結合還元 | |
CN105838675A (zh) | 一种造血干细胞无血清培养基 | |
Tobioka et al. | Mitochondria in living cells: an analysis of movements | |
Rao | Embryogenesis in flowering plants: recent approaches and prospects | |
CN105039251A (zh) | 一种pH值稳定的淋巴细胞无血清培养基及其制备方法和应用 | |
Lemonnier et al. | Comparative study of extracellular amino acids in culture of human liver and fibroblastic cells | |
Altman et al. | Somatic embryogenesis in celery: induction, control and changes in polyamines and proteins | |
CN1306569A (zh) | 稳定化的瞬时基因表达 | |
JP2000157260A (ja) | 初代前駆脂肪細胞の分化誘導方法及びその分化用培地 | |
Tasto et al. | Towards a Continuous Production of Human Mesenchymal Stromal Cells in a Chemically Defined Medium: Opportunities and Challenges for a Robust and Scalable Expansion Process | |
JP2749011B2 (ja) | 無血清培地で増殖継代可能な細胞およびその取得方法 | |
Müthing et al. | Microcarrier cultivation of bovine aortic endothelial cells in spinner vessels and a membrane stirred bioreactor | |
CN104931697A (zh) | Cd248+cd8+t细胞亚群在人升主动脉瘤病变过程中的作用 | |
Camien | A microbiological method for the determination of L-and D-aspartic acids. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160622 |